Dyadic International (DYAI) Expected to Announce Earnings on Tuesday

Dyadic International (NASDAQ:DYAI) will likely be announcing its Q4 2025 results after the market closes on Tuesday, March 31st. Analysts expect the company to announce earnings of ($0.03) per share and revenue of $1.3430 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Wednesday, March 25, 2026 at 5:00 PM ET.

Dyadic International Trading Down 8.5%

NASDAQ DYAI opened at $0.86 on Tuesday. The stock has a market cap of $31.12 million, a PE ratio of -3.58 and a beta of 1.29. Dyadic International has a 12 month low of $0.71 and a 12 month high of $1.45. The company’s 50-day moving average price is $0.83 and its 200-day moving average price is $0.95. The company has a current ratio of 2.85, a quick ratio of 2.85 and a debt-to-equity ratio of 1.92.

Hedge Funds Weigh In On Dyadic International

Several institutional investors have recently made changes to their positions in the company. Bank of America Corp DE raised its holdings in shares of Dyadic International by 16,146.7% in the fourth quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock valued at $47,000 after acquiring an additional 26,965 shares in the last quarter. Geode Capital Management LLC increased its position in Dyadic International by 13.7% during the 4th quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock valued at $284,000 after purchasing an additional 36,266 shares during the period. Finally, Landscape Capital Management L.L.C. purchased a new position in Dyadic International during the 3rd quarter valued at about $190,000. Hedge funds and other institutional investors own 27.95% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Dyadic International in a research note on Monday, December 29th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Dyadic International currently has an average rating of “Hold” and a consensus price target of $3.00.

About Dyadic International

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.